(Q74838029)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9691331%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

review article

1 reference

title

Analysis of fluoroquinolones in biological fluids by high-performance liquid chromatography (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9691331%20AND%20SRC:MED&resulttype=core&format=json

high-performance liquid chromatography

13 November 2019

main subject

1 reference

G Carlucci

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9691331%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

language of work or name

English

0 references

publication date

1 July 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9691331%20AND%20SRC:MED&resulttype=core&format=json

Journal of Chromatography

13 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9691331%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

volume

812

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9691331%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9691331%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

page(s)

343-367

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9691331%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

13 November 2019

high-performance liquid chromatography

1 reference

based on heuristic

inferred from title

cites work

The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Clinical uses of nalidixic acid analogues: the fluoroquinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Clinical utility of DNA gyrase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Mode of action, and in vitro and in vivo activities of the fluoroquinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Structure-activity relationships of the fluoroquinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Fluoroquinolone antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Chiral DNA gyrase inhibitors. 1. Synthesis and antimicrobial activity of the enantiomers of 6-fluoro-7-(1-piperazinyl)-1-(2'-trans-phenyl-1'-cyclopropyl)-1, 4-dihydro-4-oxoquinoline-3-carboxylic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Chiral DNA gyrase inhibitors. 2. Asymmetric synthesis and biological activity of the enantiomers of 9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H- pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid (ofloxacin)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

A simple isocratic high-pressure liquid chromatographic assay of quinolones in serum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Rapid HPLC assay of fluoroquinolones in clinical specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Quinolone pharmacokinetics and metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Reversed-phase ion-pair high-performance liquid chromatographic determination of fluoroquinolones in human plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Quantitation of norfloxacin, a new antibacterial agent in human plasma and urine by ion-pair reverse-phase chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of norfloxacin and ciprofloxacin concentrations in serum and urine by high-pressure liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Quantitative determination of ofloxacin, ciprofloxacin, norfloxacin and pefloxacin in serum by high pressure liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Assay of ciprofloxacin and norfloxacin in serum and urine by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic determination of norfloxacin in human tissues and plasma with fluorescence detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Sensitive high-performance liquid chromatographic assay for norfloxacin utilizing fluorescence detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic analysis of norfloxacin in human tissues and plasma with fluorescence detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic procedure for the quantitation of norfloxacin in urine, serum and tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Rapid and economical high-performance liquid chromatographic method for the determination of norfloxacin in serum using a microparticulate C18 guard cartridge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Inhibition of drug metabolism by quinolone antibiotics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

The influence of quinolone derivatives on theophylline clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Simultaneous assay of fluoroquinolones and theophylline in plasma by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

A high performance liquid chromatographic procedure for the simultaneous determination of norfloxacin and furprofen in rat plasma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic procedure for the simultaneous determination of norfloxacin, fenbufen and felbinac in rat plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Synthesis and antibacterial activities of substituted 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxyl ic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Use of quinolones in general practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Termination of magnet-unresponsive pacemaker endless loop tachycardia by carotid sinus massage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

A preliminary report on the pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in patients with chronic renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

New 4-quinolones in the treatment of urinary tract infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

The quinolones in chronic bronchitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of ofloxacin after parenteral and oral administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Simultaneous determination of ofloxacin, fenbufen and felbinac in rat plasma by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of ofloxacin in bronchoalveolar lavage fluid by high-performance liquid chromatography and fluorimetric detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of ofloxacin in human serum by high-performance liquid chromatography with column switching

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Safety and pharmacokinetics of multiple doses of intravenous ofloxacin in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Method for the determination of ofloxacin, a quinolone carboxylic acid antimicrobial, by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of ofloxacin in plasma and urine by liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic determination of ofloxacin in plasma and urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Application of high-performance liquid chromatography of some antibiotics in clinical microbiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Quantification of the enantiomers of ofloxacin in biological fluids by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Multiple-dose pharmacokinetics of ofloxacin in serum, saliva, and skin blister fluid of healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Ofloxacin in human hair determined by high performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic determination of (S)-(-)-ofloxacin and its metabolites in serum and urine using a solid-phase clean-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Utilization of hair analysis for therapeutic drug monitoring with a special reference to ofloxacin and to nicotine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Simultaneous determination of ofloxacin, norfloxacin and ciprofloxacin in human hair by high-performance liquid chromatography and fluorescence detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Effective monitoring of concentrations of ofloxacin in saliva of patients with chronic respiratory tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

A reproducible, simple and sensitive HPLC assay for determination of ofloxacin in plasma and lung tissue. Application in pharmacokinetic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

The determination of ofloxacin in human skin tissue by high-performance liquid chromatography and correlation between skin tissue concentration and serum level of ofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of ofloxacin in human plasma using high-performance liquid chromatography and fluorescence detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of ofloxacin in serum and vitreous humor of albino and pigmented rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Intracellular accumulation of ofloxacin-loaded liposomes in human synovial fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Time course of appearance of ofloxacin in human scalp hair after oral administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Ciprofloxacin concentrations in bone and muscle after oral dosing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of intravenously administered ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of ciprofloxacin and effect of repeated dosage on salivary and fecal microflora

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Penetration of ciprofloxacin into gynecological tissues following oral and intravenous administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Tissue distribution of ciprofloxacin following oral and intravenous administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Diabetes insipidus associated with dysplastic pancytopenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Distribution of ciprofloxacin in ascitic fluid following administration of a single oral dose of 750 milligrams

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Effect of dose size on bioavailability of ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Diffusion of ciprofloxacin into prostatic fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In-vitro activity of ciprofloxacin (Bay 09867)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Ciprofloxacin distribution in prostatic tissue and fluid following oral administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In-vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Concentration of ciprofloxacin in human prostatic tissue after oral administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of ciprofloxacin in cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic method for determination of ciprofloxacin in biological fluids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of ciprofloxacin in biological samples by reversed-phase high performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic method for the simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in canine serum and prostatic tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Improved high-performance liquid chromatographic determination of ciprofloxacin and its metabolites in human specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic determination of ciprofloxacin in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of ciprofloxacin in human serum by liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Dose- and sex-independent disposition of ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of high-dose intravenous ciprofloxacin in young and elderly and in male and female subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatography of ciprofloxacin and its metabolites in serum, urine and sputum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic determination of ciprofloxacin in rat brain and cerebrospinal fluid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

HPLC analysis of ciprofloxacin and ciprofloxacin metabolites in body fluids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Sensitive and selective determination of picogram amounts of ciprofloxacin and its metabolites in biological samples using high-performance liquid chromatography and photothermal post-column derivatization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of ciprofloxacin and its 7-ethylenediamine metabolite in human serum and urine by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

A direct liquid chromatographic quantitation of ciprofloxacin in microsamples of plasma with fluorometric detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Rapid liquid chromatographic assay of ciprofloxacin in human aqueous humor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of ciprofloxacin levels in chinchilla middle ear effusion and plasma by high-performance liquid chromatography with fluorescence detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Absolute oral bioavailability of ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Simultaneous determination of theophylline, enoxacin and ciprofloxacin in human plasma and saliva by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Comparative in vitro activities of ciprofloxacin and other 4-quinolones against Mycobacterium tuberculosis and Mycobacterium intracellulare

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Ciprofloxacin concentrations in human aqueous humor following intravenous administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Dose ranging study and constant infusion evaluation of ciprofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Simultaneous high-performance liquid chromatographic determination of ciprofloxacin, fenbufen and felbinac in rat plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

A simple high-performance liquid chromatographic assay for ciprofloxacin in human serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin alone and in combination in healthy elderly volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Monitoring of pefloxacin serum concentrations in intensive care unit patients: comparison of a new immunoassay with high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Recovery of pefloxacin in saliva and feces and its action on oral and fecal floras of healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatography of pefloxacin and its main active metabolites in biological fluids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Improved high-performance liquid chromatographic determination of pefloxacin and its metabolite norfloxacin in human plasma and tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of pefloxacin and its main active metabolite in human serum by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Novel amino-substituted 3-quinolinecarboxylic acid antibacterial agents: synthesis and structure-activity relationships

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Metabolism and disposition of amifloxacin in laboratory animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In vitro susceptibilities of 393 recent clinical isolates to WIN 49375, cefotaxime, tobramycin, and piperacillin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Analysis of amifloxacin in plasma and urine by high-pressure liquid chromatography and intravenous pharmacokinetics in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of amifloxacin and two of its principal metabolites in plasma and urine by high-performance liquid chromatography using automated column switching

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic determination of 6,8-difluoro-1-(2-fluoroethyl)-1,4- dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid and its metabolites in laboratory animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Metabolism of fleroxacin in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic assay and erythrocyte partitioning of fleroxacin, a new fluoroquinolone antibiotic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of the new fluoroquinolone fleroxacin and its N-demethyl and N-oxide metabolites in plasma and urine by high-performance liquid chromatography with fluorescence detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of a new quinolone, AM-833, in mice, rats, rabbits, dogs, and monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Synthesis and structure-activity relationships of novel arylfluoroquinolone antibacterial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In-vitro and in-vivo potency of five new fluoroquinolones against anaerobic bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Difloxacin metabolism and pharmacokinetics in humans after single oral doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic procedures for the determination of difloxacin and its metabolites in biological matrices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In vitro and in vivo activity of NY-198, a new difluorinated quinolone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In-vitro assessment of lomefloxacin (SC-47111)--a new quinolone derivative.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In-vitro activity of lomefloxacin in comparison with pefloxacin and ofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

The evolution of fluorinated quinolones: pharmacology, microbiological activity, clinical uses, and toxicities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of lomefloxacin in biological fluids by high-performance liquid chromatography and a microbiological method.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of lomefloxacin in human plasma by solid-phase extraction and high-performance liquid chromatography with UV detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Automated analytical systems for drug development studies. Part IV. A microdialysis system to study the partitioning of lomefloxacin across an erythrocyte membrane in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Stereospecific high-performance liquid chromatographic assay of lomefloxacin in human plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

In vitro Activity of a New Quinolone, Rufloxacin, against Nosocomial Isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of rufloxacin once daily in patients with lower respiratory tract infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Penetration of rufloxacin into human prostatic tissue and fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Rufloxacin once daily in acute exacerbations of chronic bronchitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Determination of rufloxacin, a new tricyclic fluoroquinolone in biological fluids using high-performance liquid chromatography with ultraviolet detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites, N-desmethylrufloxacin and rufloxacinsulfoxide, in urine of rhesus monkey Macaca mulatta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Analytical procedure for the determination of rufloxacin, a new pyridobenzothiazine, in human serum and urine by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High-performance liquid chromatographic determination of rufloxacin and its main active metabolite in biological fluids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

High performance liquid chromatography and preliminary pharmacokinetics of rufloxacin and its metabolites N-desmethylrufloxacin and rufloxacinsulfoxide in plasma and urine of humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Pharmacokinetics of rufloxacin in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Simultaneous determination of rufloxacin and theophylline by high-performance liquid chromatography in human plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Simultaneous determination of furprofen and rufloxacin in human plasma by high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

Simultaneous determination of rufloxacin, fenbufen and felbinac in human plasma using high-performance liquid chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9673%2898%2900274-X

10.1016/S0021-9673(98)00274-X

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9691331%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference